Topic summary

AOD-9604 and the fragment hypothesis, revisited

Compounds › Other compounds mislabelling research use only custom synthesis needs a source

This is a generated summary. It shows the 6 most-liked posts from a topic of 45, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

m.rasmussenTL216 Jul 2025#4

a.reyes, post #1: Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Reading back through what has been written here about AOD-9604, three questions come up every time and only one has ever been answered properly. Listing all three, with what I think the state of the… Go to post

I keep a log for AOD-9604 specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.

27 likes in reply to #1 12mo

j.delacroixTL3Regular17 Sep 2025#15

c.falk, post #14: Picking up post #13: that is the part I would want checked first. Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing. Two sources, same conclusion, and I could not rule out that one copied the other. Go to post

Noted, and thank you for writing it out rather than summarising it.

28 likes in reply to #14 10mo

l.vukovicTL23 Nov 2025#25

h.lindqvist, post #21: Post #18 is right about the mechanism and I think understates the practical bit. A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry. A guess, clearly labelled as one. Go to post

The reason AOD-9604 keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.

33 likes in reply to #21 9mo

l.sarkissianTL2Member11 Dec 2025#34

Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.

It is a small point and it changes the answer, which is an awkward combination.

32 likes 8mo

p.krastevTL231 Dec 2025 · edited#39

l.sarkissian, post #34: Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it. It is a small point and it changes the answer, which is an awkward combination. Go to post

When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.

That is a description of practice, not a recommendation of it.

31 likes in reply to #34 7mo

p.iyer_pharmdTL3Pharmacist16 Jan 2026#43

Source for the AOD-9604 figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.

Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.

29 likes 6mo

Read the full topic (45 posts)

This topic was referenced in

Naming conventions for research peptides and the confusion they causeCompounds › Other compounds · 25 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Research-use-only status: what it means legally and practically Compounds › Other compounds research use only custom synthesis needs a source mislabelling Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. Asking about research-use-only status directly, because I…	+72	81	44k	1d
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the…	+7	11	5.5k	20mo
When "no data" is the complete and final answer Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…	+154	165	6.3k	15mo
Why catalogue breadth is not evidence of anything Compounds › Other compounds research use only needs a source custom synthesis Under review Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. What changes if the standard account of catalogue breadth is wrong?…		2	38k	2d
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…	+100	108	1.3k	8mo

Related topics — sharing the tags mislabelling, research use only, custom synthesis

Topic	Participants	Replies	Views	Activity
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. Asking about GHRH analogues versus ghrelin mimetics…	+47	53	6.9k	2h
Follow-up: A supplier that answers analytical questions with restated claims Sourcing › Red flags documentation quality disputed mislabelling moderation A supplier that answers analytical questions with restated claims — setting out what I have, and where I think it stops being reliable. A follow-up question about supplier that I did not know to ask the first…	+74	82	2.8k	6mo
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? Compounds › Repair & healing peptides observational data needs a source BPC-157 TB-500 Solved The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I would like to…	+6	10	3.1k	1d
Documentation that appears only after payment Sourcing › Red flags documentation quality moderation mislabelling disputed Solved Documentation that appears only after payment Writing it up because I had to work it out twice and would rather nobody else did. Proposing that documentation deserves a maintained page rather than a recurring…	+113	124	13k	7mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…	+87	94	1.1k	21d